Tweets
ACR 2026 – Day 2 Report
https://t.co/H5aJMSwHwk https://t.co/gzGSaA9czB
Dr. John Cush @RheumNow ( View Tweet )
31 minutes 23 seconds ago
Are GLP-1s Doing More Than Shrinking Waistlines in PsA?
In abstract #0373, Pankti Mehta and colleagues examined patients from a longitudinal PsA cohort who initiated GLP-1 receptor agonist or dual GIP/GLP-1 therapy and compared them with matched controls. Baseline body mass https://t.co/FGCszLnS4N
Dr. John Cush @RheumNow ( View Tweet )
1 hour 46 minutes ago
📢 "We can't have a one-size-fits-all approach" – Dr. Saakshi Khattri
Hear Dr. Khattri and Lindsay Tom, PA-C, explore the latest IL-23i and JAKi data and how it impacts their PsA treatment decisions. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/MOBlwXCFuu https://t.co/2pHRO1SQCS
Dr. John Cush @RheumNow ( View Tweet )
2 hours 46 minutes ago
Scary IPAF
IPAF describes patients who have ILD plus clinical, serologic, or morphologic features of autoimmunity but who do not meet criteria for a defined connective tissue disease. The 2015 ERS/ATS criteria proposed IPAF as a research classification, not a distinct disease, https://t.co/v3ir4IHia7
Dr. John Cush @RheumNow ( View Tweet )
3 hours 45 minutes ago
Beyond Joint Inflammation: Does Early RA Control Prevent Chronic Pain and Fatigue?
Could the therapeutic window of opportunity in rheumatoid arthritis extend beyond preventing structural damage to preventing chronic pain, fatigue, and neuroimmune complications?
This is the https://t.co/WVSjwIHOAM
Dr. John Cush @RheumNow ( View Tweet )
4 hours 45 minutes ago
Might stem cells actually work in knee OA??
Possibly, only the right combo 🇰🇷
OSCA: OS (allo mesenchymal stem cells) + CAM (cartilage acellular matrix)
anti-inflamm, structural, pain
ph2a
impressive signal over placebo
& maybe tissue repair, benefit out to 5y?
#ACR26 @RheumNow https://t.co/PU3MUqxH7Q
David Liew @drdavidliew ( View Tweet )
22 hours 8 minutes ago
It's like HCQ on steroids
(metaphorical not literal, & anabolic not glucocorticoid)
TLR7/8 targeting in SLE (IFN-I, GC resistance, organ damage)
ph2: massive signal in primary, secondaries all hit, IFN-I down from w2, safety good
what a time for lupus
ABSTLB23 #ACR26 @RheumNow https://t.co/mhntxC4aT4
David Liew @drdavidliew ( View Tweet )
22 hours 8 minutes ago
Is 60-40-20 broken?
RA trial rule of thumb:
roughly 60%-40%-20% for ACR20-50-70
girocitinib (JAK1/Tyk2) vs tofacitinib
ACR20: 91% vs 75%
ACR50: 73% vs 49%
ACR70: 44% vs 25%
there will be debate (all in China, tofa exposure)
but what a meeting for H2H
ABSTLB21 #ACR26 @RheumNow https://t.co/SmOCzqqxFg
David Liew @drdavidliew ( View Tweet )
22 hours 8 minutes ago
Final #ACR2026 post (maybe? 😄)! Huge shoutout to @RheumNow and the incredible team for their phenomenal work in rheumatology education! Can’t believe it took me this long to collaborate with them, but I have a feeling this is the beginning of a long-term relationship! 🙌
anita @docdhanrajani ( View Tweet )
22 hours 8 minutes ago
@RheumNow The narrative medicine interactive session at #ACR2026 was well attended and had a lot of interesting exchange of thoughts and ideas. Holistic care of patients, attention to caregiver burnout and ensuring provider well being is the need of the hour in rheumatology.
anita @docdhanrajani ( View Tweet )
22 hours 9 minutes ago
@RheumNow 🎉 Celebrated 50 years of #PediatricRheumatology at #ACR2026! Meet the Masters: 3 pioneers reflected on the evolution of our field—from early genetics and DMARDs to biologics—and envisioned the future of precision medicine, novel therapies, and mentorship. What a treat
anita @docdhanrajani ( View Tweet )
22 hours 9 minutes ago
@RheumNow #1! 🌍 Global pediatric rheumatology workforce challenges! A survey across 32 countries found 40% lacked in-country training programs. Variable accreditation, limited funding & poor specialty awareness remain key barriers. Abstract 1483. #ACR2026
anita @docdhanrajani ( View Tweet )
22 hours 9 minutes ago
Is it the treatment or the disease?
-Multiple meds can cause SCLE: more widespread, EM,Bullous features.
-Dupilumab can cause enthesitis: if severe needs dc of medication
-Anti-CD 20 may cause IBD (Crohn’s-Like)
Great lecture from @md_chawla on Drug induced syndromes
#ACR26 https://t.co/EEQL7QNtWC
Links:
Adela Castro @AdelaCastro222 ( View Tweet )
22 hours 9 minutes ago
ACR26 summary, AI and documentation: errors on all five AI platforms tested against guidelines, and cDAPSA documented in 4.9% of PsA records @rheumnow #ACR26 Abstract#0869 Abstract#1348
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
22 hours 9 minutes ago
ACR26 summary, gut joint axis: replenishing TRBV9 CD8 T cells, a dual targeting antibody, calprotectin for gut inflammation, and outcomes of joint gastroenterology and rheumatology meetings. @rheumnow #ACR26 Abstract#1027 Abstract#2941 Abstract#1336 Abstract#2287
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
22 hours 9 minutes ago